All News

Hepatitis B (Keep)

AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

Jack Cush, MD

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.

Read Article
orthotics,afo

Orthotics in Rheumatoid Arthritis

Bita Imam, DO, PhD,  , Andres Quiceno, MD

Orthotics are cost-effective, externally applied devices designed to stabilize the joints and provide a conservative measure to alleviate joint pain and improve function. Options include therapeutic shoes, shoe inserts, hand splints/braces, wrist support and finger splints. This article reviews some of the indications on the use of orthotics in patients with RA.

Read Article
RheumNow Podcast square

Weak Data (1.24.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.

Read Article
DMARDs,biologics,RA

Getting to Remission - Without Biologics

Jack Cush, MD

Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.

Read Article
T%20cell.jpg

Functional Precision Medicine in Rheumatoid Arthritis

Jack Cush, MD

Novel research from the Medical University of Vienna demonstrates the plausible utility of functional precision medicine using immunophenotyping of blood cells with rheumatoid arthritis, to help guide treatment selection.

Read Article
RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
sick.child

Childhood Maltreatment and the Risk of Rheumatic Diseases

EurekAlert!

A UK retrospective matched open cohort study shows that children who suffered frmo abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.    

Read Article
Review of 39 imaging studies (12 MRI, 26 evaluated ultrasound) in pts w/ clinically suspect arthralgia showed variable results for imaging predicting progression from CSA to inflamm. arthritis (RA). US sensitivity/specificity = 37%/90%; MRI was 45%/84% https://t.co/uUl5i2t7ib https://t.co/ScnA7aN07N

Links:

Dr. John Cush RheumNow ( View Tweet)
NIH study of MSK disease burden finds research on neck pain as most underfunded (0.83%) followed by LBP (13.9%), OA (35.1%) & RA (66.3%) - NIAMS is low compared to other institutes. In USA, MSK dz affect 1 in 3 people, approximately 127.4 million individuals.… https://t.co/MqU9TsY6GR https://t.co/rRvUYc2yee
Dr. John Cush RheumNow ( View Tweet)
NHANES survey data on 2200 #RA pts shows dietary modification can yield reduced all-cause mortality risk. Diets w/ high Healthy Eating Index & low Dietary Inflammatory Index (DII) reduced mortality (HR 0.70; 95% CI: 0.53–0.92; adjusted P = 0.01) https://t.co/T77YQMvRQ2 https://t.co/WaCapITHGK

Links:

Dr. John Cush RheumNow ( View Tweet)
Getting to Remission - Without Biologics Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.… https://t.co/K1gUdEhk1n https://t.co/PHQafKPHpB
Dr. John Cush RheumNow ( View Tweet)
French cross-sectional study of pts on stable sc MTX x several yrs. Examined MTX polyglutamates (MTX-PGs) & disease activity in 34 RA pts (25 remission). + correlation between RA remission & high MTX-PG3 levels in pts w/ BMI <25. BMI may limit utility of PG3 levels… https://t.co/uped4oMkut https://t.co/4fmnDVHYYb
Dr. John Cush RheumNow ( View Tweet)
Worldwide, it is estimated that arthralgia treatments cost USD 4.7 Billion in 2024 and is estimated to reach USD 9.0 Billion by 2035. https://t.co/DYnbhpLAhr https://t.co/sKR8sssKNx

Links:

Dr. John Cush RheumNow ( View Tweet)
French cross-sectional study of pts on stable sc MTX x several yrs. Examined MTX polyglutamates (MTX-PGs) & disease activity in 34 RA pts (25 remission). + correlation between RA remission & high MTX-PG3 levels in pts w/ BMI <25. BMI may limit utility of PG3 levels… https://t.co/scFzVy7hhA https://t.co/sUQUHFbhaG
Dr. John Cush RheumNow ( View Tweet)
RA higher risk of Celiac Dz -- Rheumatic Dz administrative data review (2004–2013)compared 70,061 #RA w/ 276,895 controls, median F/U 9 yrs. (IQR 9–9). Celiac Prevalence higher in RA (171/70,061 = 0.24% vs 398/276895 = 0.14%; p < 0.001), more so in females w/ RA… https://t.co/SayZYvkZpV https://t.co/fcuyJ5sFk0
Dr. John Cush RheumNow ( View Tweet)
Head-to-Head Clinical Trials https://t.co/kLwVKRcnna https://t.co/XDhk9VAIin

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of predominantly older males from the Veterans Health Administration (VHA) data, shows the use of b/ts-DMARDs is not associated with a risk for multiple myeloma. From 27,540 RA pts, 30% took b/tsDMARD, 77 incident MM (HR1.32;95% CI 0.78, 2.26) https://t.co/KZLEfq8vRK https://t.co/7qLQISRCoC

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Natural RA PsO/PsA patient avoiding DMARDs and Biologics, and wants Natural therapies Features Dr. Jack Cush QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/nYhcPaC0qW https://t.co/wT80JoY4OE

Links:

Dr. John Cush RheumNow ( View Tweet)
Childhood Maltreatment and the Risk of Rheumatic Diseases A UK retrospective matched open cohort study shows that children who suffered from abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.… https://t.co/f0XMDJbvvg https://t.co/9KvpixsNFL
Dr. John Cush RheumNow ( View Tweet)
SetPoint Medical has applied to FDA for pre-market approval of Vagal nerve neuroimmune modulation device to Rx mod-severe #RA, not responding to 2 biologics. Based on RESET-RA 242 pt, 12 wk RCT showing ACR20=35% vs 24% PBO resp. SAE only 1.7%. https://t.co/d8RfXBFUSS https://t.co/Fq1qkfo1NM

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×